NCT03855956 is a NA clinical trial of KB174 in Early Cirrhosis, sponsored by Kaleido Biosciences.

Who is sponsoring NCT03855956?

NCT03855956 is sponsored by Kaleido Biosciences.

What drugs are being tested in NCT03855956?

Interventions in NCT03855956: KB174, Maltodextrin.

What condition does NCT03855956 study?

NCT03855956 studies Early Cirrhosis.

Is NCT03855956 still recruiting?

NCT03855956 is currently completed. Last updated 14 May 2020.

Last reviewed 2020-05-14 · How we verify

NCT03855956

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis

Completed NA Last updated 14 May 2020

What this trial tests

NA trial testing KB174 in Early Cirrhosis in 40 participants. Completed in 1 October 2019.

Timeline

27 February 2019

Primary endpoint
1 October 2019

1 October 2019

Quick facts

Lead sponsor	Kaleido Biosciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	40
Start date	27 February 2019
Primary completion	1 October 2019
Estimated completion	1 October 2019
Sites	4 locations across United States

Drugs / interventions tested

KB174
Maltodextrin (MALTODEXTRIN) — full drug profile →

Conditions studied

Early Cirrhosis — all drugs for Early Cirrhosis →

Sponsor

Kaleido Biosciences — full company profile →

Who can join

Adults 18 to 70, any sex, with Early Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind, controlled, clinical food study aims to explore KB174, a novel mixture of oligosaccharides, and maltodextrin, an easily digestible polysaccharide, on gut microbiome structure and function in subjects with well-compensated cirrhosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kaleido Biosciences trials

Trials by the same sponsor.

NCT04814914 — An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or · completed
NCT04486482 — A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Fu · NA · completed
NCT04508413 — A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and · NA · completed
NCT04414124 — A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients · NA · completed
NCT03933410 — UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03855956 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kaleido Biosciences
Last refreshed: 14 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03855956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing